Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression.

Abstract

Tumor relapse after radiotherapy may be due to the upregulation of programmed cell death ligand 1 (PD-L1). We demonstrated that anti-PD-L1 antibody synergizes with radiation to control local and distal tumors. CD8+T cells mediated antitumor effects of the combination therapy by the reduction of myeloid-derived suppressor cells (MDSCs) via tumor-necrosis factor (TNF)-mediated signaling. Our study provides insight into immune- and radiation-based combinational therapies.

• Authors: Liufu Deng, Hua Liang, Byron Burnette, Ralph R Weicheslbaum, Yang-Xin Fu
• Journal: Oncoimmunology (Oncoimmunology) 2014 Vol. 3 Pg. e28499 ISSN: 2162-4011 [Print] United States
• PMID: 25050217 (Publication Type: Journal Article)